Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02562443 · ClinicalTrials.gov registry record · Phase 3
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
A Phase 3 study, sponsored by Traws Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 372
- Enrollment target
NCT02562443: Clinical Trial Phase 3 study, sponsored by Traws Pharma.
NCT02562443 is a Phase 3 study that was terminated before completion, run by Traws Pharma. The registered enrollment target is 372 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02562443, a Phase 3 study, was terminated before completion, sponsored by Traws Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 372 participants
- Enrollment target
Study Summary
The study's primary objective \[in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)\], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.
Primary Outcome
The overall survival (OS) of all randomized patients (ITT population), and the overall survival of patients scored as IPSS-R very high risk.
Interventions
- DRUG rigosertib
- DRUG Any approved or standard-of-care therapy
- DRUG best supportive care (BSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2015-12-02 |
| Est. Completion | 2021-07-26 |
| Phase | Phase 3 |
Why NCT02562443 stopped before completion
NCT02562443 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 3 interventions - of which rigosertib is the first listed.
NCT02562443 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02562443 about?
NCT02562443 is a clinical study titled "Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA". The study's primary objective \[in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)\], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients wit...
What is the current status of trial NCT02562443?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 372 participants. The study started on 2015-12-02. Estimated completion is 2021-07-26.
What interventions are being tested in trial NCT02562443?
The interventions under investigation include: rigosertib (DRUG), Any approved or standard-of-care therapy (DRUG), best supportive care (BSC) (DRUG).
Who is sponsoring clinical trial NCT02562443?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02562443's enrollment target sits among peer trials
372 991st of 2000 higher than 1,009 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI